A novel antidepressant from Praxis Precision Medicines failed to outperform placebo in a pivotal study, the company said Monday, casting doubt on what was meant to be a nuanced approach to the brain’s natural regulatory system.
The drug, a once-daily oral treatment known as PRAX-114, missed its primary and secondary goals in a study enrolling about 200 patients with major depressive disorder. After two and four weeks of treatment, patients receiving PRAX-114 did not see their symptoms significantly improve compared to placebo, the company said. Praxis did not disclose details of the trial results.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
